Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.
Villa
M
M
Cardiology, Cardiac Surgery, Intensive Care, Microbiology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
Lage
E
E
Ballesteros
S
S
Cañas
E
E
Sánchez
M
M
Ordóñez
A
A
Borrego
J M
JM
Hinojosa
R
R
Cisneros
J M
JM
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018579:Patient Selection; D010750:Phosphoproteins / Q000097:blood*; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology; D011446:Prospective Studies; D013997:Time Factors; D014763:Viral Matrix Proteins / Q000097:blood*
D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir